PFS
Figure 4. · Panel A
Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu, Tibor Csöszi, Yohann Loriot, Alejo Rodriguez-Vida, Lajos Géczi, Susanna Y Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Seyda Gunduz, Ronac Mamtani, Evan Y Yu, Alvaro Montesa Pino, Urbano Anido, Mehmet A N Sendur, Gwenaelle Gravis, János Révész, Vladimir Kostorov, Olivier Huillard, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Jared Lunceford, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Nobuaki Matsubara
Clin Cancer Res 30(23) 5353-5364
PURPOSE: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in advanced urothelial carcinoma. This prespecified exploratory analysis assessed the association of tumor mutational burden (TMB) and PD-L1 combined positive score (CPS) with clinical outcomes. PATIENTS AND METHODS: TMB and PD-L1 CPS were determined via whole-exome sequencing and PD-L1 IHC 22C3 pharmDx, respectively. The association was evaluated in each treatment arm using logistic regression [objective response rate (ORR)] and Cox proportional hazards regression models (PFS and OS); one-sided (pembrolizumab monotherapy; pembrolizumab plus chemotherapy) and two-sided (chemotherapy) nominal P values were calculated. Significance was prespecified at α = 0.05 without multiplicity adjustment. Efficacy was evaluated by prespecified cutoffs of 175 mutations/exome (TMB) and CPS 10 (PD-L1). RESULTS: Of the 993 treated patients, 820 (82.6%) and 993 (100%) had evaluable TMB and CPS data, respectively. Continuous TMB was positively associated with ORR, PFS, and OS for pembrolizumab monotherapy (one-sided P < 0.001, P < 0.001, and P = 0.007, respectively); PFS and OS for pembrolizumab plus chemotherapy (one-sided P = 0.007 and P = 0.010, respectively); and OS for chemotherapy alone (two-sided P = 0.040). Continuous PD-L1 CPS showed evidence of anticipated association with ORR and PFS for pembrolizumab monotherapy. The subgroup with TMB ≥175 mutations/exome and PD-L1 CPS ≥10 had the highest PFS and OS improvements with pembrolizumab alone or with chemotherapy versus chemotherapy alone. CONCLUSIONS: These data suggest that TMB may be predictive of the response to pembrolizumab alone or with chemotherapy in advanced urothelial carcinoma.
3 个 Figure · 12 个 KM 面板
Kaplan–Meier estimates of survival by TMB cutoff for pembrolizumab plus chemotherapy vs. chemotherapy. A, PFS. B, OS.
Figure 4. · Panel A
Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. · Panel A_2
Panel A_2 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. · Panel B
Panel B 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. · Panel B_4
Panel B_4 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan–Meier estimates of survival by PD-L1 CPS cutoff for pembrolizumab monotherapy vs. chemotherapy. A, PFS. B, OS.
Figure 5. · Panel A
Panel A 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. · Panel A_2
Panel A_2 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. · Panel B
Panel B 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. · Panel B_4
Panel B_4 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan–Meier estimates of survival by PD-L1 CPS cutoff for pembrolizumab plus chemotherapy vs. chemotherapy. A, PFS. B, OS.
Figure 6. · Panel A
Panel A 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. · Panel B
Panel B 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. · Panel A_3
Panel A_3 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. · Panel B_4
Panel B_4 是同一 Figure 6. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。